tility study of PET imaging with 64Cu-DOTA labeled antibody probes against HER2 and EGFR
Not Applicable
Recruiting
- Conditions
- Breast cancer, Gastric cancer, Colorectal cancer, Glioma
- Registration Number
- JPRN-UMIN000017446
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. Severe drug hypersensitivity 2. Ischemic heart disease, cardiomyopathy, congestive heart failure and uncontrolled arrhythmia 3. Active infectious disease, interstitial pneumonia and pulmonary fibrosis 4. Organ insufficiency (bone marrow, liver and kidney) 5. Active synchronous double cancer 6. Pregnancy and lactating (including possibility and intention) 7. Decision of the physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visualization of PET imaging with 64Cu-DOTA labeled antibody probes against HER2 and EGFR. Comparison between PET imaging and expression of HER2 and EGFR.
- Secondary Outcome Measures
Name Time Method Safety of HER2- and EGFR-PET imaging. Comparison between standardized uptake value on PET imaging and expression of HER2 and EGFR. Comparison between intratumoral uptake of 64Cu-DOTA labeled antibody probes and expression of HER2 and EGFR (in specific cases).